Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Protein citrullination as a link between periodontal diseases and rheumatoid arthritis (RA) and target for development of novel drugs to treat RA. (GUMS AND JOINTS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Norway,Poland,Sweden,Germany,Denmark,Spain,Spain,United Kingdom,United Kingdom,United Kingdom,Italy,Sweden,United Kingdom
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-11-01
End date: 2014-10-31
Duration (months): 48.0
Total project cost (EUR): 7588334.62
EU funding (EUR): 5851588.0
Participants: 13
Project status: CLOSED

Autoimmunity in rheumatoid arthritis (RA) is characterised by an antibody response to citrullinated proteins. Periodontitis (PD) is largely caused by infection, in which Porphyromonas gingivalis is a major pathogen. The two diseases combine specific HLA-DRB1alleles and smoking as risk factors, and have a similar pathophysiology characterised by destructive inflammation. A possible causative link between RA and PD is based on the ability of P. gingivalis to citrullinate proteins and thereby generate autoantigens that drive autoimmunity in RA. We hypothesise that anti-citrullinated protein antibodies can be generated, in genetically susceptible individuals, as a consequence of P. Gingivalis-induced citrullination in the gingiva. In the context of genetic risk factors, during chronic exposure to danger signals, such as bacterial lipopolysacharides and DNA, tolerance to citrullinated proteins may be broken, with production of a pathogenic antibody response, which at a later time point cross-reacts with joint proteins and causes chronic RA. We will use a multidisciplinary approach (genetics, epidemiology, molecular immunology and animal models) to study susceptibility factors and immune responses in RA and PD, with an aim to identify novel etiological and pathogenic pathways, forming the basis for new therapies.

Keywords: rheumatoid arthritis,citrullination,ptm,p. gingivalis,autoimmunity
Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation (MABSOT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,Belgium,Spain,Czechia,United Kingdom,Netherlands,United Kingdom,Ireland
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-12-01
End date: 2014-09-30
Duration (months): 46.0
Total project cost (EUR): 7844900.2
EU funding (EUR): 5929064.0
Participants: 10
Project status: CLOSED

Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ transplantation as the disease progresses. At Opsona Therapeutics we have developed a novel antibody (OPN-305) which has received OMP designation (EU/3/09/638) for use in the prevention of DGF. The scientific basis of this development is the inhibition of Toll-like receptor 2 (TLR2)-mediated ischaemic reperfusion injury which has a pivotal role in the pathogenesis of DGF and its sequelae. The MABSOT project is designed to progress the development of this OMP through Phase I and II clinical trial. The successful completion of the programme will allow the continued development of OPN-305 as an OMP for the treatment of DGF in a range of solid organ transplant situations. OPN-305 development will have significant benefit to these patients and health care providers in reducing the prolonged hospitalisation of these individuals, providing greater longevity associated with the transplanted organ and enhanced quality of life for these individuals.

Keywords: transplantation,delayed graft function,kidney,solid organ transplantation
Vaccination against Shigella and ETEC: novel antigens, novel approaches (STOPENTERICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Norway,United Kingdom,Belgium,Italy,Sweden,Bangladesh,Israel,France,Ghana,Netherlands,United Kingdom,Netherlands,Switzerland
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-11-01
End date: 2017-12-31
Duration (months): 86.0
Total project cost (EUR): 16055468.58
EU funding (EUR): 11460630.0
Participants: 18
Project status: CLOSED

To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel solutions by imposing a two-fold paradigm switch: (i) to break the dogma of serotype-specificity by inducing a cross-protective immunity (ii) to improve the immunogenicity of Shigella glycoconjugates by using synthetic oligosacharides mimicking the lipopolysaccharide O-antigen. The possibilities offered by genomics/proteomics and bacterial outer membrane blebs (OMB) will be exploited to identify virulence proteins conserved throughout Shigella or ETEC isolates. For ETEC, the development of a safe, immunogenic ST (heat stable) toxoid is a priority. State-of-the-art glycochemistry and sugar-protein carrier conjugation will allow engineering optimal Shigella glycoconjugates with focus on the five most prevalent serotypes. The ultimate aim is to optimize chances for the best coverage by combining cross-protective and serotype-specific antigens, thus ensuring the development of efficient multivalent vaccines that will help reduce the burden of diarrheal diseases. At all stages of the R & D process, candidate antigens will be considered in light of immunomonitoring data obtained in naturally-infected individuals, and volunteers undergoing vaccine trials. Regarding the latter, Phase-1 clinical trials with two vaccine candidates are planned as proofs–of-concept of (i) a synthetic oligosaccharides approach mimicking Shigella O-antigens, and (ii) a Shigella OMB-based vaccines to be tested after validation of preclinical studies. STOPENTERICS is a unique combination of laboratories, platforms, vaccinology centres from academia and industry in the North and the South, integrated to successfully develop new vaccines, from R&D toward clinical trials. By promoting high-standard training capacity for young investigators, it will foster a new generation of researchers in neglected infectious diseases.

Keywords: shigella,etec,vaccine,protein,glycoconjugate,omv,immunomonitoring,clinical trial,training
Coordinating resources to assess and improve health status of migrants from Latin America (COHEMI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: Italy,Spain,Netherlands,United Kingdom,Peru,Ecuador,Bolivia, Plurinational State of
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-01-01
End date: 2013-12-31
Duration (months): 36.0
Total project cost (EUR): 2271341.73
EU funding (EUR): 1999959.84
Participants: 10
Project status: CLOSED

European health systems are committed to meeting the challenge of understanding the needs of migrant populations and adapting their services to meet these needs. The difficulties inextricably linked to this challenge are caused by the complexity of migration patterns and the differences between migrant population across EU countries. At present, the limited available data show that attempts to incorporate migrants’ health needs, in particular those of migrants from non-EU countries, into EU health systems have remained scattered and uncoordinated. COHEMI’s general objective is to coordinate referral centres dealing with specific Latin American (LA) diseases in order to provide a clear understanding of the full migration cycle in relation with the health systems in Europe and Latin America and to provide a in-depth insight into priority health-related aspects of LA migration in order to facilitate the development of and transfer of evidence and information relevant to migrant health policies.

Keywords: migrants,health systems,health care,health policy,neglected diseases,communicable diseases
High-Performance Computing Infrastructure for South East Europe’s Research Communities (HP-SEE)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to existing research infrastructures
Action type: Combination of CP & CSA
Countries involved: Greece,Bulgaria,Romania,Türkiye,Serbia,Albania,Bosnia and Herzegovina,North Macedonia,Montenegro,Moldova, Republic of,Armenia,Georgia,Azerbaijan,Hungary
Call:  (FP7-INFRASTRUCTURES-2010-2, 2010)
Start date: 2010-09-01
End date: 2013-08-31
Duration (months): 36.0
Total project cost (EUR): 3900463.0
EU funding (EUR): 2100000.0
Participants: 16
Project status: CLOSED

Core European eInfrastructure for large-scale eScience research consists of the backbone GÉANT network; distributed storage & computing infrastructure - European Grid Initiative (EGI); and the PRACE initiative providing tier-0 High Performance Computing (HPC) infrastructure. South-East European eInfrastructure initiatives aim for equal participation of the less-resourced countries of the region in the European trends. SEEREN initiative established a regional network and the SEE-GRID initiative the regional Grid, with majority of countries now equal partners in GÉANT and EGI. BSI project established the GÉANT link to the Caucasus, active until mid-2010. However, HPC involvement of the region is limited. Only few HPC installations are available, not open to cross-border research; while the less-resourced countries have no mechanism established for interfacing to the pan-European HPC initiatives. HP-SEE focuses on a number of strategic actions. First, it will link the existing and upcoming HPC facilities in the region in a common infrastructure, and provide operational solutions for it. As a complementary action, the project will establish and maintain the GÉANT link for Caucasus. Second, it will open this HPC infrastructure to a wide range of new user communities, including those of less-resourced countries, fostering collaboration and providing advanced capabilities to researchers, with an emphasis on strategic groups in computational physics, chemistry and life sciences. Finally, it will ensure establishment of national HPC initiatives, and act as a SEE bridge for PRACE. In this context, HP-SEE will aim to attract the local political & financial support for long-term sustainable eInfrastructure. HP-SEE aspires to contribute to the stabilisation and development of South-East Europe, by overcoming fragmentation in Europe and stimulating eInfrastructure development and adoption by new virtual research communities, thus enabling collaborative high-quality research across a spectrum of scientific fields.

Keywords: high-performance computing,balanced regional development,multi-disciplinary user communities
Biology and control of vector-borne infections in Europe (EDENEXT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Czechia,Italy,France,Georgia,Greece,Spain,Türkiye,United Kingdom,United Kingdom,Senegal,Spain,Denmark,France,Spain,Austria,Czechia,Hungary,Romania,Switzerland,Albania,France,Romania,Finland,Belgium,Sweden,Slovakia,Germany,Germany,Germany,Germany,Netherlands,United Kingdom,Belgium,Belgium,Portugal
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-01-01
End date: 2015-06-30
Duration (months): 54.0
Total project cost (EUR): 16368755.61
EU funding (EUR): 11981710.0
Participants: 52
Project status: CLOSED

To address the call for proposals 'Biology and control of vector-borne infections in Europe' launched by the European Commission, we want to investigate the biological, ecological and epidemiological components of vector-borne diseases (VBD) introduction, emergence and spread, and to propose innovative tools for controlling them, building on the basis of acquired knowledge. We have selected the main groups of arthropod vectors involved in the transmission of vector-borne diseases in Europe: ticks, mosquitoes, sandflies, and biting midges (Culicoides). We have also selected the main diseases of actual or possible importance in human and veterinary public health. Rodents, insectivores and rodent-borne diseases have also been considered, both for their direct importance in public health, and for the major role of rodents and insectivores as reservoir hosts of many pathogens. We have put a strong focus on vector- and disease-quantitative modelling. The resulting predictive models will be used to assess climate or environmental change scenarios, as well as vector or disease control strategies. Human behaviour and risk perception are an important component of VBD introduction, emergence and spread. The consequences triggered by VBD for human and veterinary public health in Europe are just starting to emerge in public awareness. We will also account for this aspect of human and veterinary public health in our proposal. Finally, the set of innovative research methods, tools and results obtained during the project will be a step forward a generic approach of VBD in terms of disease monitoring and early warning systems, and will reinforce the general framework for an integrated pest and disease management system. For all these aspects, we will benefit from, and amplify the strong scientific results, capacity building, and research networks established by EDEN project on emerging, vector-borne diseases in a changing European environment.

Keywords: vector,tick,rodent,sandfly,culicoides,mosquito,vector-borne,disease,biology,control,public health
Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria (AIPGENE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Sweden,Germany,Spain,Netherlands
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-01-01
End date: 2014-10-31
Duration (months): 46.0
Total project cost (EUR): 4347949.14
EU funding (EUR): 3308154.0
Participants: 7
Project status: CLOSED

Acute intermittent porphyria (AIP) is a rare genetic disease in which mutations in the porphobilinogen deaminase (PBGD) gene produce insufficient activity of a protein necessary for heme synthesis. This leads to an accumulation of toxic intermediates resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute porphyric attacks can be life-threatening and the long-term consequences include irreversible nerve damage, liver cancer and kidney failure. AIP affects 1/10,000 people in the EU and the therapies currently available do not prevent the symptoms or consequences of acute porphyric attacks. The only curative therapy is liver transplantation and thus, new curative options are clearly needed. In 2009, the European Medicines Agency granted Orphan Drug Designation to AAV5-AAT-PBGD for the treatment of AIP. AAV is a replication-incompetent virus that has been modified to deliver genes or genetic material into human tissues or cells. AAV5-AAT-PBGD acts by delivering the PBGD expression cassette directly into hepatocytes. In heterozygous AIP patient that show 50% of the normal activity the additional PBGD activity will be sufficient to prevent the accumulation of toxic metabolites and thus, to prevent porphyric attacks. the aim of this project is the clinical development of the orphan drug AAV-AAT-PBGD for use to treat AIP. The project will be performed in three different phases. In the first phase, we will develop a GMP-compliant process to produce sufficient AAV5-AAT-PBGD for clinical trials, and we will constitute the largest possible cohorts to improve the follow-up of patients and determine the clinical criteria to select patients for gene therapy. In the second phase, the safety and efficacy of AAV5-AAT-PBGD will be explored in a dose escalation clinical phase I/II trial.

Keywords: acute intermittent porphyria,porphobilinogen deaminase,heme synthesis,gene therapy,bioavailability,bioequivalence,human pharmacokinetics,pharmacodynamics.
IP Networks as a Service (MANTYCHORE)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to existing research infrastructures
Action type: Combination of CP & CSA
Countries involved: Spain,Denmark,Ireland,United Kingdom,Spain,United Kingdom,Denmark
Call:  (FP7-INFRASTRUCTURES-2010-2, 2010)
Start date: 2010-10-01
End date: 2013-06-30
Duration (months): 33.0
Total project cost (EUR): 1593689.0
EU funding (EUR): 1399740.0
Participants: 9
Project status: CLOSED

Current National Research and Education Networks (NRENs) in Europe provide connectivity services to their customers: the research and education community. Traditionally these services have been delivered on a manual basis, although some efforts towards automating the service setup and operation have been initiated. At the same time, more focus is being put in the ability of the community to control some characteristics of these connectivity services, so that users can change some of the service characteristics without having to renegotiate with the service provider. The MANTYCHORE project wants to consolidate this trend and allow the NRENs to provide a complete, flexible IP network service that allows research communities to create an IP network under their control, where they can configure: i) layer 1 -optical- ii) layer 2 - Ethernet and MPLS- and iii) layer 3 -IP addressing, internal routing, peering, firewalls- . To achieve its goals, MANTYCHORE FP7 will integrate and improve the tools developed by the past, privately funded MANTICORE projects and related initiatives (IaaS Framework efforts), and produce a robust and extensible software to operate and use the IP network service. MANTYCHORE will carry out pre-operational deployments of the IP network service at two NRENS: HEAnet and NORDUnet. Initially three communities of researchers will benefit from this service: the Nordic Health Data Network, the British Advance High Quality Media Services and the Irish Grid effort. Part of the project effort will be dedicated to consolidate and enhance the community of providers (NRENs but also commercial) and users of the IP network service. Finally, the JRAs will research two important topics to improve the IP network service: i) an infrastructure resource marketplace, to further automate the negotiation of the resources that comprise the IP network; and ii) the use of renewable energy sources to power e-Infrastructures, so that they can become carbon neutral.

Keywords: ip network service,infrastructure as a service,nren operation tools,zero-carbon,infrastructure resource marketplaces,network virtualisation,services for the research community,renewable energy
Opportunities for Data Exchange (ODE)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to policy development and Programme implementation
Action type: Coordination and support actions
Countries involved: Switzerland,Finland,Germany,United Kingdom,United Kingdom,Germany,Netherlands
Call:  (FP7-INFRASTRUCTURES-2010-2, 2010)
Start date: 2010-11-01
End date: 2012-11-30
Duration (months): 25.0
Total project cost (EUR): 759694.0
EU funding (EUR): 720000.0
Participants: 9
Project status: CLOSED

The transition from science to e-Science is happening: a data deluge emerges from publicly- funded research facilities; a massive investment of public funds into the potential answer to the grand challenges of our times. This potential can only be realised by adding an interoperable data sharing, re-use and preservation layer to the emerging eco-system of e-Infrastructures. The importance of this layer, on top of emerging connectivity and computational layers, has not yet been addressed coherently at ERA or global level. All stakeholders in the scientific process must be involved in its design this layer: policy makers, funders, infrastructure operators, data centres, data providers and users, libraries and publishers. ODE is proposed by the Alliance for Permanent Access and four of its members: CERN, Finnish Computer Centre for Science, Helmholtz Association and UK Science and Technology Funding Council. Collectively, we represent all the stakeholder groups listed above and have a significant sphere of influence within those communities. This will allow us to identify, collate, interpret and deliver evidence of emerging best practices in sharing, re-using, preserving and citing data, the drivers for these changes and barriers impeding progress, in forms suited to each audience. We will: -Enable operators, funders, designers and users of national and pan-european e-Infrastructures to compare their vision and explore shared opportunities -Provide projections of potential data re-use within research and educational communities in and beyond the ERA, their needs and differences -Demonstrate and improve understanding of best practices in the design of e-Infrastructures leading to more coherent national policies -Document success stories in data sharing, visionary policies to enable data re-use, and the needs and opportunities for interoperability of data layers to fully enable e-Science -Make that information available in readiness for FP8

Keywords: data sharing,data re-use,data preservation,e-infrastructures,e-science,scholarly communication
Socio-Economic Impact Assessment for e-Infrastructures Research Projects (ERINA+)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to policy development and Programme implementation
Action type: Coordination and support actions
Countries involved: Italy,Austria
Call:  (FP7-INFRASTRUCTURES-2010-2, 2010)
Start date: 2010-07-01
End date: 2013-01-31
Duration (months): 31.0
Total project cost (EUR): 962913.0
EU funding (EUR): 780000.0
Participants: 4
Project status: CLOSED

E-Infrastructures initiatives have a great innovation potential toward the ERA and the society at large. This is one the main results of the ERINA study, also cited in the official communication to the European Parliament “ICT Infrastructures for e-Science”, issued by the EC in April 2009. However, many projects are still not aware of the opportunity of self-assessing the potential impact of their actions, and, more important, have no instruments to do this. In the present times, when the economic crisis and the pressure from developing countries are pushing for critical budgetary decisions, policy-makers need to have concrete instruments to concentrate economic efforts and maximise their investments. With this respect, the EC and the e-Infrastructures and Geant Unit, in particular, have issued and awarded several tenders on Impact analysis. However, the ERINA+ Consortium believes that there is urgency to target also all the e-Infrastructures initiatives through a support service complementing the scientific quality of the activities. The proposed service will provide a quantitative method for assessing projects’ impact, addressing 20 projects, throughout their duration. This will be achieved through a wide outreach strategy including focus groups, workshops and a final conference, leading to the production of a final recommendations White Paper. The ERINA+ initiative is proposed by a well balanced consortium bringing together the expertise of a leading research and industrial organisation, the know-how of an internationally renowned research institute, and two innovative SMEs providing in-depth analysis and studies related to the socio-economic impact of ICT research and investments.

Keywords: e-infrastructure,impact assessment,socio-economic analysis